Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations LMI070 - mRNA splicing modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05111249 VIBRANT-HD (CLMI070C12203) Huntington's disease Phase 2 75 1. Reduction (%) of mHTT protein in cerebrospinal fluid (CSF) 2. Number of treatment emergent adverse events and serious adverse events Arm 1: Experimental; Branaplam 56 mg oral solution once weekly Arm 2: Experimental; Branaplam 112 mg oral solution once weekly Arm 3: Experimental; (C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly Arm 4: Placebo; Matching placebo oral solution once weekly Participants with early manifest Huntington's Disease Target Patients Read-out Milestone(s) Publication 2025 TBD 97 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation